ProBiotix Health has announced the launch of an instant melt formulation for YourBiotixMH, which will be showcased at this year's Vitafoods Europe show.
YourBiotixMH has been designed specifically for women during or after menopause, with the company adding that the new delivery format makes the probiotic convenient to take "anywhere and at any time."
Attendees to the tradeshow will be available to try the new peach-flavoured format at the company's exhibition stand, 4K55, between 5th and 7th May at the Fira Barcelona Gran Via, Barcelona, Spain.
Why this matters
By 2030, it is estimated that 1.2 billion women globally will be either transitioning to the menopause.
For women in this critical, life-changing period, there is a rising awareness of cardiovascular risk and a growing consumer demand for clinically substantiated ingredients that offer protective and preventive functions to support long-term wellness.
"Menopause reflects a critical turning point in women's cardiometabolic health. Research has highlighted that post-menopausal women are five times more likely to suffer a heart attack, while 77% of women aged 45 and above have raised cholesterol," said Cellan Davies, Head of Marketing, at ProBiotix.
With the shift from reactive symptom management to preventative health outcomes, this has created a growing unmet need for solutions that go beyond symptom relief, such as hot flushes and night sweats and address long-term cardiometabolic health.
"ProBiotix is uniquely positioned to meet this need by developing precision probiotic solutions backed by clinical substantiation that focus on long-term health support."
"With YourBiotixMH Instant Melt, the solution harnesses the power of our clinically validated probiotic strain LPLDL (Lactobacillus Plantarum), in combination with selected nutrients that support positive menopause outcomes, such as Isoflavones, Thiamine and vitamins D and B6."
Research conducted by the University of Reading and the University of Roehampton has already validated LPLDL's positive effects on cardiometabolic health, with results indicating that LPLDL significantly reduces total cholesterol by up to 37%, LDL by 36%, Apolipoprotein B by 28% and blood pressure by 5%.
Davies continued: "As oestrogen plays such a protective role in maintaining healthy cholesterol levels, vascular function and arterial health, these cardiometabolic health markers are crucially important to menopausal and postmenopausal women who face declining oestrogen levels throughout this challenging transitional period, impacting heart health, bone density, energy and mood."
"This can have a major impact on the workplace, disrupting women's careers and economic productivity."
With better science, care and support, women no longer need to suffer with these symptoms in silence. This is why YourBiotixMH was specifically developed to both relieve the symptoms and address long-term cardiovascular and bone health risks that accompany menopause, so that women can add life to years, not just years to life.
With tighter regulations now coming into force for the life sciences industry, including the EU monacolin ban this year regarding its pharmacological activity and potential safety risks, Davies concludes: "Many organisations are now seeking solutions that align with future regulatory and safety expectations due to evolving scrutiny around certain cholesterol-lowering ingredients, such as Monacolin K."
For nutraceutical developers, this is our period of rapid reformulation. It is causing the industry to revisit ingredient selection and reconsider other formulation opportunities that perhaps were not possible before.
"This is driving forward momentum of scientifically validated alternatives and new approaches to cardiometabolic health."